Semaglutide is what's known as a GLP-1 receptor agonist, meaning it activates the receptors of the GLP-1 (glucagon-like peptide-1) hormones that regulate blood sugar and appetite in our own bodies
Safety depends on the patient, the treatment plan, and careful medical review
And perhaps they've even sent their child to a nutritionist, dietician, and they don't see the results, Decotiis said
The SELECT cardiovascular outcomes trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% over a mean follow-up of 39.8 months, a finding that strengthens re-authorization arguments for patients with established cardiovascular disease [5]
This is primarily water and glycogen depletion alongside early fat loss
The provider type and location can significantly impact prices